美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

亚盛医药

15.31

+0.56003.80%

成交量：3,872

成交额：5.90万

市值：14.29亿

市盈率：-6.58

高：15.46

开：15.19

低：15.19

收：14.75

52周最高：37.50

52周最低：14.46

股本：9,333.04万

流通股本：7,158.28万

量比：0.77

换手率：0.01%

股息：- -

股息率：- -

每股收益(TTM):-2.3260

每股收益(LYR):-1.9957

净资产收益率：-236.63%

总资产收益率：-28.04%

市净率：17.19

市盈率(LYR):-7.67

数据加载中...

总览公司新闻资讯公告

亚盛医药盘中涨超5%，高管认购及受托人购股

亚盛医药，钢丝上的舞者

亚盛医药：主席兼执行董事杨大俊增持3.86万股总代价约115.71万港元

南方财经网

亚盛医药：受托人购买5万股公司股份以满足受限制股份单位计划

南方财经网

亚盛医药盘中涨超6%，受托人购买股份

亚盛医药(06855)：受托人就2022年受限制股份单位计划目的购买5万股

亚盛医药与北京大学达成战略合作，共筑血液肿瘤协同创新体系

亚盛医药上半年亏损同比扩大至8.17亿元

亚盛医药(06855)公布2026年中期业绩：商业化造血能力持续提升，全球化进程加速

亚盛医药受邀出席Evercore第二届中国生物科技峰会并参加炉边谈话

财报前瞻｜亚盛医药本季度营收预计增58.18%，机构观点偏乐观

亚盛医药聘任CBO、CCO分管全球业务拓展及海外商业化

亚盛医药任命首席业务拓展官和首席商务运营官

亚盛医药(06855)任命Faiçal Miyara博士为首席业务拓展官，任命Jim Ziegler为首席商务运营官

【祝贺】亚盛医药杨大俊荣登《The Medicine Maker》2026全球最具影响力人物榜

亚盛医药启动2亿美元ATM融资计划，加速奥雷巴替尼及Lisaftoclax商业化进程

亚盛医药(06855)根据2021年受限制股份单位计划授出44.07万份受限制股份单位

【EHA2026】亚盛医药多项临床数据亮相，彰显血液肿瘤领域全球创新实力

亚盛医药(06855)在2026年欧洲血液学协会(EHA)年会公布多项临床进展

亚盛医药(06855)：受托人就2022年受限制股份单位计划目的购买11万股

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/AAPG/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":15.31,"timestamp":1791826698033,"preClose":14.75,"halted":0,"volume":3872,"delay":0,"changeRate":0.03796610169491529,"floatShares":71582800,"shares":93330405,"eps":-2.325979,"marketStatus":"交易中","change":0.56,"latestTime":"10-12 13:44:18 EDT","open":15.19,"high":15.4551,"low":15.19,"amount":59026.25872,"amplitude":0.017973,"askPrice":15.49,"askSize":426,"bidPrice":15.19,"bidSize":39,"shortable":3,"etf":0,"ttmEps":-2.325979,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791835200000},"marketStatusCode":2,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":14.75,"preHourTrading":{"tag":"盘前","latestPrice":15.03,"preClose":14.75,"latestTime":"09:25 EDT","volume":84,"amount":1263.865932,"timestamp":1791811546156,"change":0.28,"changeRate":0.018983,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":14.75,"preClose":14.75,"latestTime":"16:10 EDT","volume":3,"amount":43.5,"timestamp":1791576603910,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.767322},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-28.04%","roe":"-236.63%","lyrEps":-1.995679,"volumeRatio":0.767322,"shares":93330405,"dividePrice":0,"high":15.4551,"amplitude":0.017973,"preClose":14.75,"low":15.19,"week52Low":14.455,"pbRate":"17.19","psRate":"14.89","week52High":37.5,"institutionHeld":0,"latestPrice":15.31,"committee":-0.832258,"eps":-2.325979,"divideRate":0,"volume":3872,"delay":0,"ttmEps":-2.325979,"open":15.19,"prevYearClose":26.24,"prevWeekClose":14.75,"prevMonthClose":16.31,"prevQuarterClose":16.31,"fiveDayClose":14.605,"twentyDayClose":16.41,"sixtyDayClose":18.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"date":"2026-08-19","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2026/06","expectedEps":-0.44,"defaultRemindTime":1787126400000,"name":null,"time":"盘前","dateTimestamp":1787112000000,"actualEps":null},{"date":"2026-03-25","symbol":"AAPG","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":null,"defaultRemindTime":1774468800000,"name":null,"time":"盘后","dateTimestamp":1774411200000,"actualEps":null},{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盘前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.7143,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7143,"analysts":7,"updateTime":1781150400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2026-10-09","current":-6.582175,"percent":0.995305,"low":-76.454813,"twenty":-35.391731,"median":-17.937257,"eighty":-9.524782,"high":-5.996207,"avg":-23.690394,"sd":16.91092,"marketCap":1322595698.71},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-12","current":-22.941741,"twenty":-59.475774,"median":-35.943012,"eighty":-31.122625,"marketCap":3735810338.07},{"date":"2025-09-19","current":-21.785524,"twenty":-59.316014,"median":-35.857966,"eighty":-29.943039,"marketCap":3550375801.58},{"date":"2025-09-26","current":-21.102028,"twenty":-59.062646,"median":-35.66937,"eighty":-29.751262,"marketCap":3428719452.06},{"date":"2025-10-03","current":-22.266298,"twenty":-59.025902,"median":-35.30284,"eighty":-28.699054,"marketCap":3625414266.5},{"date":"2025-10-10","current":-21.050291,"twenty":-58.738293,"median":-35.189473,"eighty":-26.732175,"marketCap":3423480133.18},{"date":"2025-10-17","current":-19.80269,"twenty":-58.191808,"median":-34.731922,"eighty":-24.468638,"marketCap":3221889328.22},{"date":"2025-10-24","current":-19.801335,"twenty":-57.904825,"median":-34.477812,"eighty":-23.569995,"marketCap":3222890223.42},{"date":"2025-10-31","current":-19.321494,"twenty":-57.532716,"median":-34.141844,"eighty":-22.943557,"marketCap":3150231208.59},{"date":"2025-11-07","current":-18.112503,"twenty":-56.69325,"median":-33.992043,"eighty":-22.558349,"marketCap":2949090425.48},{"date":"2025-11-14","current":-19.583345,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"marketCap":3199584585.23},{"date":"2025-11-21","current":-17.547753,"twenty":-55.765092,"median":-33.408485,"eighty":-22.122489,"marketCap":2860955000.96},{"date":"2025-11-28","current":-18.539078,"twenty":-55.318442,"median":-33.361942,"eighty":-21.796498,"marketCap":3034915066.08},{"date":"2025-12-05","current":-18.33416,"twenty":-53.27811,"median":-33.187028,"eighty":-21.590149,"marketCap":3005486168.49},{"date":"2025-12-12","current":-17.062052,"twenty":-48.796704,"median":-32.920123,"eighty":-21.073758,"marketCap":2802301628.68},{"date":"2025-12-19","current":-16.188794,"twenty":-48.517949,"median":-32.72391,"eighty":-20.125041,"marketCap":2665447409.6},{"date":"2025-12-26","current":-15.347054,"twenty":-48.514967,"median":-32.664532,"eighty":-19.801335,"marketCap":2537308174.25},{"date":"2026-01-02","current":-14.520508,"twenty":-48.239817,"median":-32.57809,"eighty":-19.656119,"marketCap":2406972911.39},{"date":"2026-01-09","current":-15.636938,"twenty":-46.480698,"median":-32.420873,"eighty":-19.300607,"marketCap":2595562368.02},{"date":"2026-01-16","current":-14.792082,"twenty":-45.997596,"median":-31.846105,"eighty":-19.073232,"marketCap":2461528990.12},{"date":"2026-01-23","current":-14.451393,"twenty":-45.706429,"median":-31.242401,"eighty":-18.892753,"marketCap":2402559084.95},{"date":"2026-01-30","current":-13.594278,"twenty":-43.897892,"median":-30.891003,"eighty":-18.486342,"marketCap":2268064814.82},{"date":"2026-02-06","current":-13.215954,"twenty":-42.7913,"median":-29.979764,"eighty":-18.329609,"marketCap":2208187061.91},{"date":"2026-02-13","current":-13.314281,"twenty":-42.590497,"median":-29.752899,"eighty":-18.136415,"marketCap":2236446544.83},{"date":"2026-02-20","current":-13.322258,"twenty":-42.10164,"median":-29.751262,"eighty":-17.934704,"marketCap":2235292402.77},{"date":"2026-02-27","current":-13.022247,"twenty":-41.475205,"median":-29.511221,"eighty":-17.157024,"marketCap":2206480506.48},{"date":"2026-03-06","current":-12.669019,"twenty":-41.161756,"median":-28.176938,"eighty":-16.734267,"marketCap":2131116747.44},{"date":"2026-03-13","current":-12.688953,"twenty":-40.378179,"median":-26.74375,"eighty":-16.137082,"marketCap":2141399622.46},{"date":"2026-03-20","current":-11.937263,"twenty":-39.521832,"median":-25.944924,"eighty":-15.566094,"marketCap":2005434649.33},{"date":"2026-03-27","current":-12.020857,"twenty":-39.289753,"median":-24.396919,"eighty":-15.439715,"marketCap":2161491459.44},{"date":"2026-04-02","current":-13.548587,"twenty":-39.152841,"median":-23.731199,"eighty":-15.186721,"marketCap":2444436047.79},{"date":"2026-04-10","current":-12.693217,"twenty":-38.895939,"median":-23.387346,"eighty":-14.745986,"marketCap":2308441702.51},{"date":"2026-04-17","current":-13.620079,"twenty":-38.882244,"median":-22.946281,"eighty":-14.465216,"marketCap":2481253103.51},{"date":"2026-04-24","current":-12.083101,"twenty":-38.84865,"median":-22.780777,"eighty":-14.008358,"marketCap":2199221373.05},{"date":"2026-05-01","current":-11.527627,"twenty":-38.758432,"median":-22.499202,"eighty":-13.791914,"marketCap":2098243441.9},{"date":"2026-05-08","current":-10.968155,"twenty":-38.515761,"median":-22.389807,"eighty":-13.684651,"marketCap":2004129088.99},{"date":"2026-05-15","current":-10.082774,"twenty":-38.444183,"median":-22.266298,"eighty":-13.539734,"marketCap":1846775928.57},{"date":"2026-05-22","current":-10.707594,"twenty":-38.225934,"median":-22.137659,"eighty":-13.395768,"marketCap":1956144727.44},{"date":"2026-05-29","current":-10.055476,"twenty":-38.129026,"median":-21.923528,"eighty":-13.314281,"marketCap":1843351578.24},{"date":"2026-06-05","current":-8.909894,"twenty":-37.937734,"median":-21.785524,"eighty":-13.216389,"marketCap":1635661877.38},{"date":"2026-06-12","current":-8.93641,"twenty":-37.865895,"median":-21.603031,"eighty":-13.157057,"marketCap":1639076784.73},{"date":"2026-06-18","current":-8.353042,"twenty":-37.752402,"median":-21.278471,"eighty":-13.101714,"marketCap":1535636323.4},{"date":"2026-06-26","current":-7.824164,"twenty":-37.62092,"median":-21.066691,"eighty":-13.023474,"marketCap":1430786980.62},{"date":"2026-07-02","current":-8.952074,"twenty":-37.472757,"median":-20.67449,"eighty":-12.989985,"marketCap":1637864621.41},{"date":"2026-07-10","current":-9.338033,"twenty":-37.371981,"median":-19.946515,"eighty":-12.776282,"marketCap":1707700089.2},{"date":"2026-07-17","current":-9.151372,"twenty":-36.963176,"median":-19.801335,"eighty":-12.672971,"marketCap":1678950333.06},{"date":"2026-07-24","current":-9.04646,"twenty":-36.577605,"median":-19.676085,"eighty":-12.361815,"marketCap":1659751775.25},{"date":"2026-07-31","current":-8.626077,"twenty":-36.450857,"median":-19.539859,"eighty":-12.179575,"marketCap":1585151449.4},{"date":"2026-08-07","current":-9.281807,"twenty":-36.322679,"median":-19.321494,"eighty":-11.987055,"marketCap":1708580872.07},{"date":"2026-08-14","current":-9.158138,"twenty":-36.125575,"median":-19.172925,"eighty":-11.879713,"marketCap":1687515849.52},{"date":"2026-08-21","current":-7.057849,"twenty":-35.947221,"median":-19.05933,"eighty":-11.591162,"marketCap":1541157743.83},{"date":"2026-08-28","current":-7.528669,"twenty":-35.921968,"median":-18.891573,"eighty":-11.215925,"marketCap":1645140637.76},{"date":"2026-09-04","current":-7.512769,"twenty":-35.896367,"median":-18.539078,"eighty":-10.909833,"marketCap":1642057095.97},{"date":"2026-09-11","current":-6.726657,"twenty":-35.844587,"median":-18.43689,"eighty":-10.516338,"marketCap":1472033722.18},{"date":"2026-09-18","current":-6.328251,"twenty":-35.78272,"median":-18.34244,"eighty":-10.147967,"marketCap":1385839347.04},{"date":"2026-09-25","current":-6.198771,"twenty":-35.717333,"median":-18.302386,"eighty":-9.993282,"marketCap":1355442980.28},{"date":"2026-10-02","current":-6.256521,"twenty":-35.554336,"median":-18.13243,"eighty":-9.623881,"marketCap":1368865778.06},{"date":"2026-10-09","current":-6.039007,"twenty":-35.391731,"median":-17.937257,"eighty":-9.524782,"marketCap":1322595698.71}],"updateTime":1791825921588},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674828354","title":"亚盛医药盘中涨超5%，高管认购及受托人购股","url":"https://stock-news.laohu8.com/highlight/detail?id=2674828354","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674828354?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 10:22","pubTimestamp":1791771720,"startTime":"0","endTime":"0","summary":"10月12日，亚盛医药(06855.HK)盘中涨超5%，截至10时20分，涨5.24%，报29.70港元/股，成交额2228.02万港元。消息面上，9月28日，亚盛医药发布公告，于2026年9月28日，受托人就2022年受限制股 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261012/c680574977.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261012/c680574977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4139","AAPG","BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674783546","title":"亚盛医药，钢丝上的舞者","url":"https://stock-news.laohu8.com/highlight/detail?id=2674783546","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674783546?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 12:28","pubTimestamp":1791520080,"startTime":"0","endTime":"0","summary":"亚盛医药的故事，便在这两种时态之间，被无数投资者反复掂量。2026年的盛夏，亚盛医药向美国证监会递交文件，拟发行最高2亿美元美国存托凭证。02武田交易亚盛医药的研发开支主要在奥雷巴替尼（耐立克）和利沙托克拉（利生妥）。2024年6月，亚盛与武田制药就奥雷巴替尼达成海外选择权协议，换回1亿美元首付款，另有7500万美元的股权投资。钢丝上的舞者，最忌的不是走得慢，而是失去平衡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2026-10-09/doc-iniuqywm7008124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK4139","AAPG","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670725684","title":"亚盛医药：主席兼执行董事杨大俊增持3.86万股 总代价约115.71万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670725684","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670725684?lang=zh_cn&edition=fundamental","pubTime":"2026-09-28 22:50","pubTimestamp":1790607000,"startTime":"0","endTime":"0","summary":"南财智讯9月28日电，亚盛医药（06855.HK）发布自愿公告，公司执行董事兼董事会主席杨大俊博士于2026年9月23日至25日在场内认购合共3.86万股公司普通股，总代价约为115.71万港元，平均价约为每股29.95港元，占公司已发行股本总额约0.01%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885543023.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885543023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4139","BK1574","AAPG","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670256826","title":"亚盛医药：受托人购买5万股公司股份以满足受限制股份单位计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2670256826","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670256826?lang=zh_cn&edition=fundamental","pubTime":"2026-09-28 22:44","pubTimestamp":1790606640,"startTime":"0","endTime":"0","summary":"南财智讯9月28日电，亚盛医药（06855.HK）发布自愿公告，2026年9月28日，公司受托人就2022年受限制股份单位计划目的于场内购买合共5万股现有股份，占总股本约0.01%，总代价为142.8万港元，每股平均代价约28.56港元。紧随上述购买后，受托人于场内购买的现有股份总数为271.5万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885536325.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885536325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06855","BK1161","AAPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139813","title":"亚盛医药盘中涨超6%，受托人购买股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139813","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669139813?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 09:48","pubTimestamp":1789955280,"startTime":"0","endTime":"0","summary":"9月21日，亚盛医药(06855.HK)盘中涨超6%，截至9时45分，涨6.02%，报31.34港元/股，成交额4157.29万港元。消息面上，亚盛医药公布，于2026年9月17日，受托人就2022年受限制股份单位计划目的 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260921/c680109576.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260921/c680109576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4139","06855","BK1161","AAPG","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668967431","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划目的购买5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668967431","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668967431?lang=zh_cn&edition=fundamental","pubTime":"2026-09-17 21:01","pubTimestamp":1789650089,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年9月17日，受托人就2022年受限制股份单位计划目的于场内购买合共5万股现有股份以在归属后满足受限制股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","AAPG","06855","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690236","title":"亚盛医药与北京大学达成战略合作，共筑血液肿瘤协同创新体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690236","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667690236?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 07:40","pubTimestamp":1789429200,"startTime":"0","endTime":"0","summary":"双方将整合临床资源与创新研发优势，共筑血液肿瘤协同创新体系，加快该领域创新成果的临床转化，为患者带来更多获益。北京大学人民医院作为北大医学体系的重要组成部分和国家医学中心建设单位，在血液肿瘤等重大疾病诊疗与研究领域积淀深厚。亚盛医药一直以来与北京大学有着深厚的合作根基与相互的信任。\" 此次战略合作标志着亚盛医药与北京大学在血液肿瘤领域的协同创新进入新阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5046875_ZH46875_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5046875_ZH46875_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","AAPG","06855","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660472128","title":"亚盛医药上半年亏损同比扩大至8.17亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660472128","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660472128?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 09:38","pubTimestamp":1787189880,"startTime":"0","endTime":"0","summary":"8月20日，亚盛医药（06855）发布截至2026年6月30日止6个月的未经审计综合业绩。报告期内，公司收益为3.02亿元，按固定汇率计算，同比增长29.3%；归母净亏损为8.17亿元，而去年同期亏损5.91亿元。2026年上半年，公司的行政开支达1.19亿元，同比增长19.3%，主要是由于购股权及受限制股份单位开支增加所致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847307477.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847307477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06855","AAPG","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660347943","title":"亚盛医药(06855)公布2026年中期业绩：商业化造血能力持续提升，全球化进程加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2660347943","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660347943?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 07:36","pubTimestamp":1787182583,"startTime":"0","endTime":"0","summary":"智通财经APP了解到，亚盛医药今日公布2026年中期业绩。2026年上半年，公司实现总收入3.02亿元人民币，同比增长29%。在耐立克与利生妥两大商业化产品的双引擎驱动下，公司自我造血能力持续加强。报告期内，公司产品销售收入达到人民币2.82亿元，同比增长33%。截至报告期末，公司总货币资金约19亿元人民币，资金储备充足，为全球研发与商业化拓展提供坚实支撑。亚盛医药正全面快速推进这些全球注册III期临床研究，全球创新将迎来收获期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK4139","06855","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659168288","title":"亚盛医药受邀出席Evercore第二届中国生物科技峰会并参加炉边谈话","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168288","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659168288?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 21:13","pubTimestamp":1786626780,"startTime":"0","endTime":"0","summary":"中国苏州2026年8月13日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司管理层将出席于2026年8月17日-19日在上海浦东丽思卡尔顿酒店举办的Evercore第二届中国生物科技峰会。会议期间，公司管理层将参与由Evercore研究团队主持的炉边谈话，并开展一对一投资者交流会。因此，该等前瞻性陈述不应被视为对未来事件的预测。无论出现新信息、未来事件或其他情况，亚盛医药均无义务更新或修订任何前瞻性陈述。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5025874_ZH25874_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5025874_ZH25874_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["EVR","06855","KURE","BK1161","BK4139","BK4127","BK1574","AAPG","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181890937","title":"财报前瞻 ｜亚盛医药本季度营收预计增58.18%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1181890937","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181890937?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 09:37","pubTimestamp":1786498646,"startTime":"0","endTime":"0","summary":"亚盛医药将于2026年08月19日美股盘前发布最新季度财报，市场聚焦盈利改善节奏与商业化推进进度。市场一致预期显示，本季度亚盛医药营收预计为5,097.60万美元，同比增加58.18%；调整后每股收益预计为-0.26美元，同比改善73.17%；EBIT预计为-1.17亿美元，同比下降43.11%；由于缺乏公司端明确口径，毛利率与净利润或净利率的本季度量化指引未见披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜亚盛医药本季度营收预计增58.18%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656419833","title":"亚盛医药聘任CBO、CCO分管全球业务拓展及海外商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656419833","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656419833?lang=zh_cn&edition=fundamental","pubTime":"2026-08-03 09:11","pubTimestamp":1785719460,"startTime":"0","endTime":"0","summary":"8月3日，亚盛医药（06855）发布公告，公司宣布两项高管任命，聘任FaialMiyara博士担任CBO统筹全球业务拓展，JimZiegler出任CCO，负责大中华区以外全球产品商业化运营，二人直接向董事长兼首席执行官杨大俊博士汇报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033829261521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033829261521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AAPG","BK4139","BK1161","LU2294711713.HKD","LU0823414551.USD","LU2249611893.SGD","LU2506951792.HKD","BK4009","LU0823414478.USD","BK1574","06855","LU2357125470.USD","CCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656845349","title":"亚盛医药任命首席业务拓展官和首席商务运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2656845349","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656845349?lang=zh_cn&edition=fundamental","pubTime":"2026-08-03 08:25","pubTimestamp":1785716700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AAPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656346342","title":"亚盛医药(06855)任命Faiçal Miyara博士为首席业务拓展官，任命Jim Ziegler为首席商务运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2656346342","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656346342?lang=zh_cn&edition=fundamental","pubTime":"2026-08-03 07:37","pubTimestamp":1785713832,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 发布公告，公司任命Faial Miyara博士为首席业务拓展官，负责亚盛医药的全球业务拓展工作;并任命Jim Ziegler为首席商务运营官，负责公司产品在大中华地区以外的全球市场的商业化运营。Miyara博士和Ziegler先生直接向公司董事长兼首席执行官杨大俊博士汇报。Miyara博士在全球大型制药公司和生物技术公司中拥有超过20年的肿瘤领域商务拓展经验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK4139","BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654992650","title":"【祝贺】亚盛医药杨大俊荣登《The Medicine Maker》2026全球最具影响力人物榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2654992650","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654992650?lang=zh_cn&edition=fundamental","pubTime":"2026-07-27 10:26","pubTimestamp":1785119160,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年7月27日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司董事长兼首席执行官杨大俊博士荣登国际知名医药产业媒体《The Medicine Maker》2026年度\"The Power List\"，在小分子领域TOP10名单中位居第三位。《The Medicine Maker》是全球制药产业链极具影响力的专业媒体，聚焦药物研发、CMC 工艺开发、产业化落地与新药商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5012304_ZH12304_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5012304_ZH12304_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1574","AAPG","BK4139","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652294251","title":"亚盛医药启动2亿美元ATM融资计划，加速奥雷巴替尼及Lisaftoclax商业化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2652294251","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652294251?lang=zh_cn&edition=fundamental","pubTime":"2026-07-19 19:42","pubTimestamp":1784461320,"startTime":"0","endTime":"0","summary":"7月19日，亚盛医药（06855）发布公告，宣布于2026年7月20日向美国证券交易委员会提交了一份F-3表格的注册声明，计划通过建议ATM计划按市价出售最多达2亿美元的美国存托股份。此次计划的实施将允许公司灵活控制股份的出售时间和数量，且不需要在香港进行公开发售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607193811765025.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607193811765025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AAPG","06855","BK4139","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647858376","title":"亚盛医药(06855)根据2021年受限制股份单位计划授出44.07万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2647858376","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647858376?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 08:53","pubTimestamp":1782780809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 发布公告，截至本公告日期，已根据2021年受限制股份单位计划向2021年受限制股份单位计划的453名获选人士授出44.07万份受限制股份单位，相当于44.07万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4139","BK1574","06855","AAPG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2643122602","title":"【EHA2026】亚盛医药多项临床数据亮相，彰显血液肿瘤领域全球创新实力","url":"https://stock-news.laohu8.com/highlight/detail?id=2643122602","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643122602?lang=zh_cn&edition=fundamental","pubTime":"2026-06-15 09:25","pubTimestamp":1781486700,"startTime":"0","endTime":"0","summary":"展示数据涉及公司两大重磅产品——中国首个上市的第三代BCR-ABL抑制剂奥雷巴替尼和中国首个上市的国产原创Bcl-2选择性抑制剂利沙托克拉，全面展现了公司在血液肿瘤领域的深厚布局和全球创新实力。利沙托克拉在髓系肿瘤的真实世界数据也为其临床价值提供了强有力的佐证。亚盛医药首席医学官翟一帆博士表示：\"本届EHA年会上，奥雷巴替尼、利沙托克拉的多项临床进展获得展示，进一步证实了这两款重磅产品在全球血液肿瘤领域的治疗价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4983227_ZH83227_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4983227_ZH83227_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AAPG","BK1161","BK1574","06855","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228118","title":"亚盛医药(06855)在2026年欧洲血液学协会(EHA)年会公布多项临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228118","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228118?lang=zh_cn&edition=fundamental","pubTime":"2026-06-15 07:29","pubTimestamp":1781479754,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 公布，公司核心产品的17项临床进展已在2026年欧洲血液学协会年会上精彩亮相，其中包括8项壁报展示。2026年欧洲血液学协会 年会于2026年6月11日至2026年6月14日在瑞典斯德哥尔摩举办。利沙托克拉在髓系肿瘤的真实世界数据也为其临床价值提供了强有力的佐证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药(06855)在2026年欧洲血液学协会(EHA)年会公布多项临床进展","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK1161","BK4139","BK1574","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642287999","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划目的购买11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642287999","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642287999?lang=zh_cn&edition=fundamental","pubTime":"2026-06-11 21:31","pubTimestamp":1781184682,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年6月11日，受托人就2022年受限制股份单位计划目的于场内购买合共11万股现有股份以在归属后满足受限制股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK1161","BK4139","BK1574","AAPG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}